Medicus Pharma CSO granted shares, 100K options

Medicus Pharma’s Chief Scientific Officer received stock options and common shares as equity compensation, increasing his direct ownership stake.

Rhea-AI Filing Summary

Medicus Pharma Ltd. (MDCX) reported that Chief Scientific Officer Brennan Edward J. received equity awards on September 4, 2026. He was granted 100,000 stock options with an exercise price of $0.1705 per common share, expiring on September 4, 2031, and 588,235 common shares at $0.1705 per share. The option is scheduled to vest quarterly in four equal installments over one year, and his directly held common share position increased to 674,735 shares. No Rule 10b5-1 trading plan is reported for these awards.

Insider Trade Summary

Grant/Award: 688,235 shares

Grant/Award 2 txns

Insider Brennan Edward J.

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	100,000	$0.00	$0.00
Grant/Award	Common Shares, no par value	588,235	$0.1705	$100K

Holdings After Transaction: Stock Option (right to buy) — 100,000 contracts (Direct); Common Shares, no par value — 674,735 shares (Direct)

Footnotes (1)

1. F1. The option was granted on September 4, 2026. The option is scheduled to vest quarterly in four equal installments over one year.

Key Figures

Stock options granted: 100,000 options Option exercise price: $0.1705 per share Option expiration date: September 4, 2031 +4 more

7 metrics

Stock options granted 100,000 options Grant to Chief Scientific Officer on September 4, 2026

Option exercise price $0.1705 per share Exercise price for 100,000 options granted on September 4, 2026

Option expiration date September 4, 2031 Expiration of stock options granted to Chief Scientific Officer

Common shares granted 588,235 shares Common share award on September 4, 2026

Grant price for common shares $0.1705 per share Price reported for 588,235 common shares awarded

Direct common shares after grant 674,735 shares Directly held by Chief Scientific Officer after September 4, 2026 award

Option vesting schedule 4 equal quarterly installments over 1 year Vesting terms of 100,000 option grant

Key Terms

Stock Option, Common Shares, vest

3 terms

Stock Option financial

"The option was granted on September 4, 2026."

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

Common Shares financial

"underlying_security_title: "Common Shares""

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

vest financial

"The option is scheduled to vest quarterly in four equal installments over one year."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

What equity awards did Medicus Pharma (MDCX) grant to Brennan Edward J. on September 4, 2026?

On September 4, 2026, Brennan Edward J., Chief Scientific Officer of Medicus Pharma, received 100,000 stock options with an exercise price of $0.1705 per share and 588,235 common shares at $0.1705 per share as equity compensation.

What are the key terms of the stock options granted by MDCX to its Chief Scientific Officer?

The Chief Scientific Officer was granted 100,000 stock options on September 4, 2026, with an exercise price of $0.1705 per common share and an expiration date of September 4, 2031. The options are scheduled to vest quarterly in four equal installments over one year.

How many Medicus Pharma (MDCX) common shares did the Chief Scientific Officer acquire and at what price?

On September 4, 2026, the Chief Scientific Officer acquired 588,235 common shares of Medicus Pharma at a price of $0.1705 per share, reported as a grant or award of common shares held directly.

What is Brennan Edward J.’s direct common share ownership in MDCX after these transactions?

Following the September 4, 2026 grant of common shares, Brennan Edward J. directly holds 674,735 common shares of Medicus Pharma. This figure reflects his position after the reported acquisition of 588,235 common shares on that date.

How do the vesting terms work for the Medicus Pharma stock options granted to the Chief Scientific Officer?

The option grant of 100,000 shares is scheduled to vest quarterly in four equal installments over one year. This means one-quarter of the options will vest at each quarterly vesting date during the one-year period following the grant.

Were the Medicus Pharma (MDCX) insider transactions reported under a Rule 10b5-1 trading plan?

No. The filing reports that the September 4, 2026 equity awards to the Chief Scientific Officer were not made pursuant to a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 05:01 PM Accepted by SEC EDGAR 09/08/2026 - 05:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brennan Edward J.

(Last) (First) (Middle)

300 CONSHOHOCKEN STATE ROAD

SUITE 200

(Street)

W.CONSHOHOCKEN PENNSYLVANIA 19428

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Medicus Pharma Ltd. [ MDCX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares, no par value	09/04/2026		A		588,235	A	$0.1705	674,735	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.1705	09/04/2026		A		100,000		(1)	09/04/2031	Common Shares	100,000	$0	100,000	D

Explanation of Responses:

1. The option was granted on September 4, 2026. The option is scheduled to vest quarterly in four equal installments over one year.

	/s/ Raza Bokhari, as Attorney-in-Fact, for Edward J. Brennan	09/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)